Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2008

01-05-2008 | Letter to the Editor

XRCC1 Arg399Gln and RAD51 5′UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients

Authors: Sandra Costa, Daniela Pinto, Deolinda Pereira, Helena Rodrigues, Jorge Cameselle-Teijeiro, Rui Medeiros, Fernando Schmitt

Published in: Breast Cancer Research and Treatment | Issue 1/2008

Login to get access

Excerpt

Breast cancer (BC) is the most common type of cancer in female, including Portugal, where this disease presents the highest incidence and mortality rates [1]. BC risk factors, like prolonged exposure to estrogen and/or ionizing radiation, BRCA1, BRCA2, TP53, ATM and CHEK2 mutations [2, 3], are related with an increased chance of DNA damage, acting as initiators of cellular alterations. DNA repair pathways are critical processes in order to maintain genome integrity. Therefore, genetic polymorphisms in DNA repair genes are common events [4]. We previously showed correlations of some of these genetic variations, as XRCC1 Arg399Gln, RAD51 5’UTR G135C and XRCC3 Thr241Met, with changeable BC susceptibility [5]. …
Literature
1.
Pinheiro PS, Tycznski JE, Bray F et al (2003) Cancer Incidence and mortality in Portugal. Eur J Cancer 39:2507–2520PubMedCrossRef
2.
Dumitrescu RG, Cotarla I (2005) Understanding breast cancer risk – where do we stand in 2005? J Cell Mol Med 9:208–221PubMedCrossRef
3.
4.
Mohrenweiser HW, Xi T, Vazquez-Matias J et al (2002) Identification of 127 amino acid substitution variants in screening 37 DNA repair genes in humans. Cancer Epidemiol Biomarkers Prev 11:1054–1064PubMed
5.
Costa S, Pinto D, Pereira D et al (2006) DNA repair polymorphisms might contribute differentially on familial and sporadic breast cancer susceptibility: a study on a Portuguese population. Breast Cancer Res Treat 103:209–217PubMedCrossRef
6.
Au WW, Navasumrit P, Ruchirawat M (2004) Use of biomarkers to characterize functions of polymorphic DNA repair genotypes. Int J Hyg Environ Health 207:301–313PubMedCrossRef
7.
Qu T, Morii E, Oboki K et al (2005) Micronuclei in EM9 cells expressing polymorphic forms of human XRCC1. Cancer Lett 221:91–95PubMedCrossRef
8.
Georgakilas AG, Bennett PV, Sutherland BM (2002) High efficiency detection of bi-stranded abasic clusters in gamma-irradiated DNA by putrescine. Nucleic Acids Res 30:2800–2808PubMedCrossRef
9.
Sutherland BM, Bennett PV, Cintron-Torres N et al (2002) Clustered DNA damages induced in human hematopoietic cells by low doses of ionizing radiation. J Radiat Res (Tokyo) 43(Suppl):S149–S152CrossRef
10.
Sutherland BM, Bennett PV, Sutherland JC et al (2002) Clustered DNA damages induced by x rays in human cells. Radiat Res 157:611–616PubMedCrossRef
11.
Ward JF (1995) Radiation mutagenesis: the initial DNA lesions responsible. Radiat Res 142:362–368PubMedCrossRef
12.
Goodhead DT, Thacker J, Cox R (1993) Weiss Lecture. Effects of radiations of different qualities on cells: molecular mechanisms of damage and repair. Int J Radiat Biol 63:543–556PubMedCrossRef
13.
Gray NK (1998) Translational control by repressor proteins binding to the 5’UTR of mRNAs. Methods Mol Biol 77:379–397PubMed
14.
Henning W, Sturzbecher HW (2003) Homologous recombination and cell cycle checkpoints: Rad51 in tumour progression and therapy resistance. Toxicology 193:91–109PubMedCrossRef
Metadata
Title
XRCC1 Arg399Gln and RAD51 5′UTR G135C polymorphisms and their outcome in tumor aggressiveness and survival of Portuguese breast cancer patients
Authors
Sandra Costa
Daniela Pinto
Deolinda Pereira
Helena Rodrigues
Jorge Cameselle-Teijeiro
Rui Medeiros
Fernando Schmitt
Publication date
01-05-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9637-1

Other articles of this Issue 1/2008

Breast Cancer Research and Treatment 1/2008 Go to the issue

Epidemiology

Low-dose medical radiation exposure and breast cancer risk in women under age 50 years overall and by estrogen and progesterone receptor status: results from a case–control and a case–case comparison

Clinical Trial

Fulvestrant (Faslodex™) in advanced breast cancer: clinical experience from a Belgian cooperative study

Preclinical Study

FBXW7 and DNA copy number instability

Epidemiology

Active and passive smoking, IL6, ESR1, and breast cancer risk

Preclinical Study

Quantitative hypermethylation of a small panel of genes augments the diagnostic accuracy in fine-needle aspirate washings of breast lesions

Epidemiology

Smoking and risk of breast cancer in carriers of mutations in BRCA1 or BRCA2 aged less than 50 years
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits